Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
308 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01367665 | STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma | completed | Phase 2 | 1,232 | Hoffmann-La RocheINDUSTRY | 37 | Jun 6, 2019 | clinicaltrials |
| NCT02467907 | Safety and Efficacy of Bevacizumab in Combination With Carboplatin and Paclitaxel for Metastatic, Recurrent or Persistent Cervical Cancer | completed | Phase 2 | 152 | Hoffmann-La RocheINDUSTRY | 18 | Jun 3, 2019 | clinicaltrials |
| NCT02472145 | An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy | completed | Phase 2 / Phase 3 | 326 | Janssen Research & Development, LLCINDUSTRY | 14 | Mar 19, 2019 | clinicaltrials |
| NCT01907100 | Nintedanib (BIBF 1120) in Mesothelioma | terminated | Phase 2 / Phase 3 | 545 | Boehringer IngelheimINDUSTRY | 27 | Mar 18, 2019 | clinicaltrials |
| NCT00782067 | Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia | completed | Phase 2 | 116 | Novartis PharmaceuticalsINDUSTRY | 12 | Nov 15, 2018 | clinicaltrials |
| NCT01693614 | Safety and Efficacy of BKM120 in Relapsed and Refractory NHL | completed | Phase 2 | 72 | Novartis PharmaceuticalsINDUSTRY | 8 | Sep 28, 2018 | clinicaltrials |
| NCT00915018 | Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer(NEFERTT) | completed | Phase 2 | 479 | Puma Biotechnology, Inc.INDUSTRY | 35 | Aug 22, 2018 | clinicaltrials |
| NCT01860638 | A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma | completed | Phase 2 | 296 | Hoffmann-La RocheINDUSTRY | 15 | Apr 30, 2018 | clinicaltrials |
| NCT01453205 | A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | completed | Phase 2 | 187 | MedImmune LLCINDUSTRY | 11 | Mar 12, 2018 | clinicaltrials |
| NCT01472887 | SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients(STARLYTE) | completed | Phase 2 | 61 | SanofiINDUSTRY | 9 | Jan 25, 2018 | clinicaltrials |
| NCT00545688 | A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer. | completed | Phase 2 | 417 | Hoffmann-La RocheINDUSTRY | 18 | Aug 15, 2017 | clinicaltrials |
| NCT01172548 | Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST)(INV555) | completed | Phase 2 | 132 | Novartis PharmaceuticalsINDUSTRY | 12 | May 31, 2017 | clinicaltrials |
| NCT01641939 | A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer | terminated | Phase 2 / Phase 3 | 415 | Hoffmann-La RocheINDUSTRY | 28 | May 12, 2017 | clinicaltrials |
| NCT00384176 | First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX(HORIZON III) | completed | Phase 2 / Phase 3 | 1,814 | AstraZenecaINDUSTRY | 28 | Apr 14, 2017 | clinicaltrials |
| NCT00719264 | Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer | completed | Phase 2 | 365 | Novartis PharmaceuticalsINDUSTRY | 21 | Mar 20, 2017 | clinicaltrials |
| NCT01401166 | Participant Preference of Subcutaneous (SC) Versus Intravenous (IV) Herceptin (Trastuzumab) in Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer(PrefHER) | completed | Phase 2 | 488 | Hoffmann-La RocheINDUSTRY | 12 | Mar 6, 2017 | clinicaltrials |
| NCT03069508 | Clemizole HCl for Subjects With Hepatocellular Carcinoma | unknown | Phase 2 | 12 | Eiger Group International, Inc.INDUSTRY | 1 | Mar 3, 2017 | clinicaltrials |
| NCT01110668 | Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST) | completed | Phase 2 | 2 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 28, 2017 | clinicaltrials |
| NCT01744691 | A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion | completed | Phase 2 | 145 | Pharmacyclics LLC.INDUSTRY | 9 | Feb 27, 2017 | clinicaltrials |
| NCT00880269 | Efficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML) | completed | Phase 2 | 59 | Novartis PharmaceuticalsINDUSTRY | 12 | Feb 23, 2017 | clinicaltrials |
| NCT01374451 | Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET(COOPERATE-2) | terminated | Phase 2 | 160 | Novartis PharmaceuticalsINDUSTRY | 19 | Dec 20, 2016 | clinicaltrials |
| NCT00903175 | Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma(RECORD-3) | completed | Phase 2 | 471 | Novartis PharmaceuticalsINDUSTRY | 19 | Nov 8, 2016 | clinicaltrials |
| NCT00444587 | A Study of Herceptin (Trastuzumab) in Combination With 2nd-Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer. | completed | Phase 2 | 114 | Hoffmann-La RocheINDUSTRY | 8 | Jun 21, 2016 | clinicaltrials |
| NCT01286077 | Velcade Consolidation Bone Study | completed | Phase 2 | 106 | Janssen-Cilag International NVINDUSTRY | 8 | May 30, 2016 | clinicaltrials |
| NCT01297491 | Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer(BASALT-1) | completed | Phase 2 | 63 | Novartis PharmaceuticalsINDUSTRY | 18 | Mar 11, 2016 | clinicaltrials |
| NCT00490646 | A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast Cancer | completed | Phase 2 | 50 | R-PharmINDUSTRY | 5 | Mar 10, 2016 | clinicaltrials |
| NCT01124864 | A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy. | completed | Phase 2 | 153 | Novartis PharmaceuticalsINDUSTRY | 10 | Mar 2, 2016 | clinicaltrials |
| NCT02598414 | The Role of Indocyanine Green (ICG) Fluorescence Imaging on Anastomotic Leak in Robotic Colorectal Surgery | unknown | Phase 2 / Phase 3 | 102 | Acibadem UniversityOTHER | 1 | Nov 24, 2015 | clinicaltrials |
| NCT00565448 | Docetaxel in Combination With Cisplatin-5-fluorouracil for the Induction Treatment of Nasopharyngeal Carcinoma in Children and Adolescents | completed | Phase 2 | 75 | SanofiINDUSTRY | 14 | Jul 30, 2015 | clinicaltrials |
| NCT00908232 | Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VD(SEQUENTIAL) | completed | Phase 2 | 163 | Janssen-Cilag International NVINDUSTRY | 10 | Jan 15, 2015 | clinicaltrials |
| NCT00343239 | Docetaxel in Locally Advanced Gastric Adenocarcinoma(NEOTAX) | completed | Phase 2 | 59 | SanofiINDUSTRY | 1 | Nov 4, 2014 | clinicaltrials |
| NCT00576758 | GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma | completed | Phase 2 | 175 | Hoffmann-La RocheINDUSTRY | 17 | Aug 19, 2014 | clinicaltrials |
| NCT00441168 | Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma | terminated | Phase 2 | 30 | Janssen-Cilag International NVINDUSTRY | 7 | Mar 21, 2014 | clinicaltrials |
| NCT00502736 | A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Malignant Bone Disease. | completed | Phase 2 | 13 | Hoffmann-La RocheINDUSTRY | 1 | Jan 22, 2014 | clinicaltrials |
| NCT00575887 | Efficacy of Protracted Temozolomide in Patients With Progressive High Grade Glioma | completed | Phase 2 | 25 | Marmara UniversityOTHER | 1 | Dec 20, 2013 | clinicaltrials |
| NCT00558103 | Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer | completed | Phase 2 | 163 | GlaxoSmithKlineINDUSTRY | 28 | Feb 4, 2013 | clinicaltrials |
| NCT00382720 | Docetaxel and Oxaliplatin in Gastric Cancer | completed | Phase 2 | 275 | SanofiINDUSTRY | 12 | Jan 7, 2013 | clinicaltrials |
| NCT01128543 | Lapatinib in Combination With Vinorelbine | completed | Phase 2 | 29 | GlaxoSmithKlineINDUSTRY | 1 | Dec 12, 2012 | clinicaltrials |
| NCT00004884 | Docetaxel and Gemcitabine Compared With Docetaxel and Cisplatin in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer | completed | Phase 2 | 96 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 8 | Sep 24, 2012 | clinicaltrials |
| NCT00023842 | BCG With or Without Mitomycin in Treating Patients With Bladder Cancer | completed | Phase 2 | 97 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 6 | Sep 24, 2012 | clinicaltrials |
| NCT00025298 | Chemotherapy Plus Radiation Therapy With or Without Amifostine in Treating Patients With Locally Advanced Cancer of the Nasopharynx | terminated | Phase 2 | 5 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 6 | Sep 24, 2012 | clinicaltrials |
| NCT00110045 | Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant | completed | Phase 2 | 171 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 7 | Sep 24, 2012 | clinicaltrials |
| NCT00246571 | Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer | completed | Phase 2 | 217 | PfizerINDUSTRY | 12 | Jul 12, 2012 | clinicaltrials |
| NCT01290406 | BEZ235 Trial in Patients With Advanced Endometrial Carcinoma | withdrawn | Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 12 | Jun 21, 2012 | clinicaltrials |
| NCT00286130 | Safety and Efficacy of Folfox6 + Cetuximab Versus Folfiri +Cetuximab in Patients With Metastatic Colorectal Cancer | completed | Phase 2 | 150 | Central European Cooperative Oncology GroupOTHER | 13 | May 1, 2012 | clinicaltrials |
| NCT00325234 | Pemetrexed-Carboplatin and Gemcitabine-Vinorelbine in Advanced Breast Cancer | completed | Phase 2 | 135 | Eli Lilly and CompanyINDUSTRY | 5 | May 20, 2011 | clinicaltrials |
| NCT00826852 | Weekly Docetaxel and Four Weekly Carboplatin in Non-small Cell Lung Cancer Carbo-Tax | completed | Phase 2 | 49 | SanofiINDUSTRY | 1 | Jul 27, 2010 | clinicaltrials |
| NCT00191854 | Gemcitabine Combinations in Metastatic Breast Cancer (MBC), 1st Line | completed | Phase 2 | 147 | Eli Lilly and CompanyINDUSTRY | 6 | Mar 2, 2010 | clinicaltrials |
| NCT00174772 | Pulmonart: Docetaxel - Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 72 | SanofiINDUSTRY | 8 | Feb 17, 2010 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials